Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Bone remodelling and bone loss are controlled by a balance between the tumour necrosis factor family molecule osteoprotegerin ligand (OPGL) and its decoy receptor osteoprotegerin (OPG). In addition, OPGL regulates lymph node organogenesis, lymphocyte development and interactions between T cells and dendritic cells in the immune system. The OPGL receptor, RANK, is expressed on chondrocytes, osteoclast precursors and mature osteoclasts. OPGL expression in T cells is induced by antigen receptor engagement, which suggests that activated T cells may influence bone metabolism through OPGL and RANK. Here we report that activated T cells can directly trigger osteoclastogenesis through OPGL. Systemic activation of T cells in vivo leads to an OPGL-mediated increase in osteoclastogenesis and bone loss. In a T-cell-dependent model of rat adjuvant arthritis characterized by severe joint inflammation, bone and cartilage destruction and crippling, blocking of OPGL through osteoprotegerin treatment at the onset of disease prevents bone and cartilage destruction but not inflammation. These results show that both systemic and local T-cell activation can lead to OPGL production and subsequent bone loss, and they provide a novel paradigm for T cells as regulators of bone physiology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“RANKL is produced by numerous cell types including cells of the osteoblast lineage (46,47) and activated T cells (42,48,49).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“T Cells express both soluble and membrane-bound forms of RANKL (49,50), and both forms are implicated in focal bone erosions associated with inflammatory arthritis (26,49).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“Within the developed immune system, RANKL is expressed by T cells (42), RANK is expressed by dendritic cells (49), and OPG is expressed by B lymphocytes and dendritic cells (4,70).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“However, RANK and RANKL knockout mice had normal Peyer's patches and intact splenic architecture (49,62), indicating that the development of lymph nodes and secondary lymphoid organs can be differentially regulated.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“RANKL inhibition via recombinant OPG treatment also results in marked suppression of bone erosions and osteoclasts in several rodent models, including adjuvant arthritis (26,49,177,232,233), collagen-induced arthritis (26,181,233), and TNF-mediated arthritis (136, 234).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationOPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 1×
“We show that: (1) p66 is serine phosphorylated upon treatment with hydrogen peroxide (H2O2) or irradiation with ultraviolet light; (2) ablation of p66 enhances cellular resistance to apoptosis induced by H2O2 or ultraviolet light; (3) a serinephosphorylation defective mutant of p66 cannot restore the normal stress res…”
BackgroundSelf-citationRAG-1-deficient mice have no mature B and T lymphocytes
Mombaerts, P., Iacomini, J., Johnson, R. S., Herrup, K., Tonegawa, S., & Papaioannou, V. E. (1992) · Cell · doi:10.1016/0092-8674(92)90030-g · Cited by 2,931
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Self-citationROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS
Feldmann, M., Brennan, F. M., & Maini, R. N. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.397 · Cited by 2,514
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Kotake, S., Udagawa, N., Takahashi, N., Matsuzaki, K., Itoh, K., Ishiyama, S., Saito, S., Inoue, K., Kamatani, N., Gillespie, M. T., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5703 · Cited by 1,696
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Self-citationWong, B. R., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalachikov, S., Cayani, E., Bartlett, F. S., Frankel, W. N., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25190 · Cited by 1,042
Cited by
Items 201–300 of 1,007
The potential role of interleukin‐17 in the immunopathology of periodontal disease
Takahashi, K., Azuma, T., Motohira, H., Kinane, D. F., & Kitetsu, S. (2005) · Journal of Clinical Periodontology · doi:10.1111/j.1600-051x.2005.00676.x · Cited by 208
Novel host response therapeutic approaches to treat periodontal diseases
Kirkwood, K. L., Cirelli, J. A., Rogers, J. E., & Giannobile, W. V. (2007) · Periodontology 2000 · doi:10.1111/j.1600-0757.2006.00166.x · Cited by 208
OSCAR is a collagen receptor that costimulates osteoclastogenesis in DAP12-deficient humans and mice
Barrow, A. D., Raynal, N., Andersen, T. L., Slatter, D. A., Bihan, D., Pugh, N., Cella, M., Kim, T., Rho, J., Negishi-Koga, T., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45913 · Cited by 207
Immune Function and Diversity of Osteoclasts in Normal and Pathological Conditions
Madel, M.-B., Ibáñez, L., Wakkach, A., de Vries, T. J., Teti, A., Apparailly, F., & Blin-Wakkach, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01408 · Cited by 206
Regulatory T Cells Protect from Local and Systemic Bone Destruction in Arthritis
Zaiss, M. M., Frey, B., Hess, A., Zwerina, J., Luther, J., Nimmerjahn, F., Engelke, K., Kollias, G., Hünig, T., Schett, G., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903841 · Cited by 205
“RANKL, a member of the TNF family, is expressed on the mesenchymal cells and on activated T cells, which illustrates the tight link between immune activation and bone (7).”
BackgroundWooley, P., & Schwarz, E. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302202 · Cited by 203
Osteoimmunology and the influence of pro-inflammatory cytokines on osteoclasts
Zupan, J., Jeras, M., & Marc, J. (2013) · Biochemia Medica · doi:10.11613/bm.2013.007 · Cited by 202
IL-23 Is Critical for Induction of Arthritis, Osteoclast Formation, and Maintenance of Bone Mass
Adamopoulos, I. E., Tessmer, M., Chao, C.-C., Adda, S., Gorman, D., Petro, M., Chou, C.-C., Pierce, R. H., Yao, W., Lane, N. E., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003986 · Cited by 200
Ziolkowska, M., Kurowska, M., Radzikowska, A., Luszczykiewicz, G., Wiland, P., Dziewczopolski, W., Filipowicz‐Sosnowska, A., Pazdur, J., Szechinski, J., Kowalczewski, J., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10388 · Cited by 200
Pike, J. W., & Meyer, M. B. (2012) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2012.03.004 · Cited by 86
Walsh, M. C., & Choi, Y. (2003) · Cytokine & Growth Factor Reviews · doi:10.1016/s1359-6101(03)00027-3 · Cited by 200
“was demonstrated that treating adjuvant-induced arthritis in Lewis rats with OPG had no discernible effect on inflammation, but prevented bone loss and cartilage destruction [88].”
BackgroundInfluentialBone loss: Factors that regulate osteoclast differentiation - an update
Roux, S., & Orcel, P. (2000) · Arthritis Research & Therapy · doi:10.1186/ar127 · Cited by 196
Osteoclasts, Master Sculptors of Bone
Veis, D. J., & O'Brien, C. A. (2023) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-031521-040919 · Cited by 193
Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity
Lam, J., Nelson, C. A., Ross, F. P., Teitelbaum, S. L., & Fremont, D. H. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13890 · Cited by 194
T Lymphocytes Amplify the Anabolic Activity of Parathyroid Hormone through Wnt10b Signaling
Terauchi, M., Li, J.-Y., Bedi, B., Baek, K.-H., Tawfeek, H., Galley, S., Gilbert, L., Nanes, M. S., Zayzafoon, M., Guldberg, R., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.07.010 · Cited by 193
Self-citationThe role of T lymphocytes in bone metabolism
Weitzmann, M. N., & Pacifici, R. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00324.x · Cited by 192
The Interplay between the Bone and the Immune System
Mori, G., D'Amelio, P., Faccio, R., & Brunetti, G. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/720504 · Cited by 193
Yao, Z., Li, P., Zhang, Q., Schwarz, E. M., Keng, P., Arbini, A., Boyce, B. F., & Xing, L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m512624200 · Cited by 192
Inflammatory diseases and bone fragility
Briot, K., Geusens, P., Em Bultink, I., Lems, W. F., & Roux, C. (2017) · Osteoporosis International · doi:10.1007/s00198-017-4189-7 · Cited by 191
Interplay between interferon and other cytokine systems in bone metabolism
Takayanagi, H., Sato, K., Takaoka, A., & Taniguchi, T. (2005) · Immunological Reviews · doi:10.1111/j.0105-2896.2005.00337.x · Cited by 191
Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption.
Nakamura, M., Udagawa, N., Matsuura, S., Mogi, M., Nakamura, H., Horiuchi, H., Saito, N., Hiraoka, B. Y., Kobayashi, Y., Takaoka, K., et al. (2003) · Endocrinology · doi:10.1210/en.2003-0717 · Cited by 191
Hofbauer, L. C., Neubauer, A., & Heufelder, A. E. (2001) · Cancer · doi:10.1002/1097-0142(20010801)92:3<460::aid-cncr1344>3.0.co;2-d · Cited by 215
Osteoimmunology: A Current Update of the Interplay Between Bone and the Immune System
Guder, C., Gravius, S., Burger, C., Wirtz, D. C., & Schildberg, F. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00058 · Cited by 190
“T helper (Th) cells of the lymphoid lineage, specifically Th17, promote osteoblast maturation with the secretion of IL-17F (132), while B cells are capable of OPG production to ensure OC supervision (133).”
BackgroundMechanisms of Disease: the link between RANKL and arthritic bone disease
Schett, G., Hayer, S., Zwerina, J., Redlich, K., & Smolen, J. S. (2005) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0036 · Cited by 191
Mechanisms of bone loss in inflammatory arthritis: diagnosis and therapeutic implications.
Goldring, S. R., & Gravallese, E. M. (2000) · Arthritis Research · doi:10.1186/ar67 · Cited by 188
Human T-cell leukemia virus type I and adult T-cell leukemia
Matsuoka, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206551 · Cited by 191
“Kong et al. (1999) identified abnormal expression of RANKL on activated T lymphocytes and postulated that this gene is associated with bone loss and joint destruction in inflammatory arthritis.”
BackgroundKitaura, H., Sands, M. S., Aya, K., Zhou, P., Hirayama, T., Uthgenannt, B., Wei, S., Takeshita, S., Novack, D. V., Silva, M. J., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.8.4838 · Cited by 190
“Because T lymphocytes, when activated, express RANKL (10), we eliminated these cells in the marrow graft and prevented their development during the course of the experiment with appropriate Abs.”
BackgroundInfluentialDynamic visualization of RANKL and Th17-mediated osteoclast function
Kikuta, J., Wada, Y., Kowada, T., Wang, Z., Sun-Wada, G.-H., Nishiyama, I., Mizukami, S., Maiya, N., Yasuda, H., Kumanogoh, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65054 · Cited by 189
“…detecting bone resorption at local sites on the bone surface (Supplemental Osteoclastogenic RANKL is mainly supplied from osteoblasts, osteocytes, and/or stromal cells in bone marrow, although RANKL has also been reported to be expressed by diverse immune cell types such as T lymphocytes (24, 25).”
Biggs, T. E., Baker, S. T., Botham, M. S., Dhital, A., Barton, C. H., & Perry, V. H. (2001) · European Journal of Immunology · doi:10.1002/1521-4141(200107)31:7<2060::aid-immu2060>3.0.co;2-l · Cited by 53
IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-κB
Abu-Amer, Y. (2001) · Journal of Clinical Investigation · doi:10.1172/jci10530 · Cited by 188
“Conversely, Th2secreted cytokines which include IL-4, IL-10, and IL-13 are immunosuppressive in nature and exert antiinflammatory and anti-osteoclastogenic effects (33, 56, 59).”
BackgroundStructural Changes in the Forefoot of Individuals with Diabetes and a Prior Plantar Ulcer
Robertson, D. D., Mueller, M. J., Smith, K. E., Commean, P. K., Pilgram, T., & Johnson, J. E. (2002) · The Journal of Bone & Joint Surgery · doi:10.2106/00004623-200208000-00016 · Cited by 188
Kanzaki, H., Wada, S., Narimiya, T., Yamaguchi, Y., Katsumata, Y., Itohiya, K., Fukaya, S., Miyamoto, Y., & Nakamura, Y. (2017) · Frontiers in Physiology · doi:10.3389/fphys.2017.00351 · Cited by 187
“In normal physiological circumstances, RANKL is principally expressed by mesenchymal cells of the osteoblast lineage, but in states of skeletal inflammation (Kong et al., 1999), as well as in periodontitis (Kawai et al., 2006), RANKL is produced in abundance by lymphocytes.”
BackgroundBioactive fatty acids: role in bone biology and bone cell function
Watkins, B. (2001) · Progress in Lipid Research · doi:10.1016/s0163-7827(00)00016-3 · Cited by 188
Yamamoto, N., Sakai, F., Kon, S., Morimoto, J., Kimura, C., Yamazaki, H., Okazaki, I., Seki, N., Fujii, T., & Uede, T. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17778 · Cited by 187
PATHOGENESIS OF RHEUMATOID ARTHRITIS
Panayi, G. S., Corrigall, V. M., & Pitzalis, C. (2001) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70204-0 · Cited by 189
Crotti, T. N., Smith, M. D., Weedon, H., Ahern, M. J., Findlay, D. M., Kraan, M., Tak, P. P., & Haynes, D. R. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.12.1047 · Cited by 186
Bone Damage in Rheumatoid Arthritis: Mechanistic Insights and Approaches to Prevention
Karmakar, S., Kay, J., & Gravallese, E. M. (2010) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2010.03.003 · Cited by 186
The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis
Haynes, D. R., Crotti, T. N., Potter, A. E., Loric, M., Atkins, G. J., Howie, D. W., & Findlay, D. M. (2001) · The Journal of Bone and Joint Surgery. British volume · doi:10.1302/0301-620x.83b6.0830902 · Cited by 186
Meednu, N., Zhang, H., Owen, T., Sun, W., Wang, V., Cistrone, C., Rangel‐Moreno, J., Xing, L., & Anolik, J. H. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39489 · Cited by 182
Molecular Pathogenicity of the Oral Opportunistic Pathogen Actinobacillus actinomycetemcomitans
Henderson, B., Nair, S. P., Ward, J. M., & Wilson, M. (2003) · Annual Review of Microbiology · doi:10.1146/annurev.micro.57.030502.090908 · Cited by 183
Geusens, P. P., Landewé, R. B. M., Garnero, P., Chen, D., Dunstan, C. R., Lems, W. F., Stinissen, P., van der Heijde, D. M. F. M., van der Linden, S., & Boers, M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21896 · Cited by 182
Ashcroft, A. J., Cruickshank, S. M., Croucher, P. I., Perry, M. J., Rollinson, S., Lippitt, J. M., Child, J. A., Dunstan, C., Felsburg, P. J., Morgan, G. J., et al. (2003) · Immunity · doi:10.1016/s1074-7613(03)00326-1 · Cited by 182
Biphasic and Dosage-Dependent Regulation of Osteoclastogenesis by β-Catenin
Wei, W., Zeve, D., Suh, J. M., Wang, X., Du, Y., Zerwekh, J. E., Dechow, P. C., Graff, J. M., & Wan, Y. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.05980-11 · Cited by 181
“In contrast, pathological stimulation of osteoclast activities occurs in osteoporosis (14a, 14b, 17a), arthritis (13, 17), and bone metastasis of cancers (20a, 28a).”
BackgroundOsteopenia in HIV-infected patients: is it the disease or is it the treatment?
Knobel, H., Guelar, A., Vallecillo, G., Nogués, X., & Díez, A. (2001) · AIDS · doi:10.1097/00002030-200104130-00022 · Cited by 181
Witten, P. E., Hansen, A., & Hall, B. K. (2001) · Journal of Morphology · doi:10.1002/jmor.1065 · Cited by 180
Osteoporosis in inflammatory joint diseases
Roux, C. (2011) · Osteoporosis International · doi:10.1007/s00198-010-1319-x · Cited by 180
“T lymphocytes stimulate osteoclast formation [63], and Treg cells suppress this phenomenon [64].”
BackgroundWeitzmann, M. N. (2017) · Toxicologic Pathology · doi:10.1177/0192623317735316 · Cited by 177
Landewé, R., van der Heijde, D., Klareskog, L., van Vollenhoven, R., & Fatenejad, S. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22143 · Cited by 177
Kitaura, H., Kimura, K., Ishida, M., Kohara, H., Yoshimatsu, M., & Takano-Yamamoto, T. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/181849 · Cited by 176
Estrogen prevents bone loss through transforming growth factor β signaling in T cells
Gao, Y., Qian, W.-P., Dark, K., Toraldo, G., Lin, A. S. P., Guldberg, R. E., Flavell, R. A., Weitzmann, M. N., & Pacifici, R. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0404888101 · Cited by 177
Bozec, A., Zaiss, M. M., Kagwiria, R., Voll, R., Rauh, M., Chen, Z., Mueller-Schmucker, S., Kroczek, R. A., Heinzerling, L., Moser, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007764 · Cited by 175
Cells of the synovium in rheumatoid arthritis. Osteoclasts.
Schett, G. A. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2110 · Cited by 214
Roux, S., Amazit, L., Meduri, G., Guiochon-Mantel, A., Milgrom, E., & Mariette, X. (2002) · American Journal of Clinical Pathology · doi:10.1309/bpet-f2pe-p2bd-j3p3 · Cited by 173
Nagy, V., & Penninger, J. M. (2015) · Gerontology · doi:10.1159/000371845 · Cited by 171
Self-citationByon, C. H., Sun, Y., Chen, J., Yuan, K., Mao, X., Heath, J. M., Anderson, P. G., Tintut, Y., Demer, L. L., Wang, D., et al. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.222547 · Cited by 172
Tateiwa, D., Yoshikawa, H., & Kaito, T. (2019) · Cells · doi:10.3390/cells8080818 · Cited by 172
“When osteoprotegerin, which is a decoy receptor of RANKL, was administered to arthritis rat models, bone destruction was regulated [112].”
BackgroundMethodRANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases
Baud’huin, M., Lamoureux, F., Duplomb, L., Rédini, F., & Heymann, D. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7104-0 · Cited by 170
Blimp1-mediated repression of negative regulators is required for osteoclast differentiation
Nishikawa, K., Nakashima, T., Hayashi, M., Fukunaga, T., Kato, S., Kodama, T., Takahashi, S., Calame, K., & Takayanagi, H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912779107 · Cited by 170
Nishikawa, M., Myoui, A., Tomita, T., Takahi, K., Nampei, A., & Yoshikawa, H. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11227 · Cited by 164
Kohli, S., & Kohli, V. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.83401 · Cited by 167
The role of TNF-α in rheumatoid arthritis: a focus on regulatory T cells
Farrugia, M., & Baron, B. (2016) · Journal of Clinical and Translational Research · doi:10.18053/jctres.02.201603.005 · Cited by 167
Maintaining homeostatic control of periodontal bone tissue
Hathaway‐Schrader, J. D., & Novince, C. M. (2021) · Periodontology 2000 · doi:10.1111/prd.12368 · Cited by 167
Hofbauer, L. C., & Heufelder, A. E. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6702 · Cited by 169
Fu, Q., Manolagas, S. C., & O'Brien, C. A. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00356-06 · Cited by 166
Nosaka, K., Miyamoto, T., Sakai, T., Mitsuya, H., Suda, T., & Matsuoka, M. (2002) · Blood · doi:10.1182/blood.v99.2.634 · Cited by 168
Weitzmann, M. N., Cenci, S., Rifas, L., Haug, J., Dipersio, J., & Pacifici, R. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.2.328 · Cited by 164
“((9,10))The bulk of the recent data are now in favor of the hypothesis that T cells (both CD4(1) and CD8(1)) are stimulatory to osteoclastogenesis.”
BackgroundResultInfluentialSignaling crosstalk between RANKL and interferons in osteoclast differentiation.
Takayanagi, H., Kim, S., & Taniguchi, T. (2002) · Arthritis Research · doi:10.1186/ar581 · Cited by 181
Chiba, A., Oki, S., Miyamoto, K., Hashimoto, H., Yamamura, T., & Miyake, S. (2004) · Arthritis & Rheumatism · doi:10.1002/art.11489 · Cited by 164
High d(+)glucose concentration inhibits RANKL-induced osteoclastogenesis
Wittrant, Y., Gorin, Y., Woodruff, K., Horn, D., Abboud, H. E., Mohan, S., & Abboud-Werner, S. L. (2008) · Bone · doi:10.1016/j.bone.2008.02.006 · Cited by 164
Identification of cell cycle–arrested quiescent osteoclast precursors in vivo
Mizoguchi, T., Muto, A., Udagawa, N., Arai, A., Yamashita, T., Hosoya, A., Ninomiya, T., Nakamura, H., Yamamoto, Y., Kinugawa, S., et al. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200806139 · Cited by 164
“RANKL-defi cient (RANKL / ) mice also exhibit severe osteopetrosis because of a lack of osteoclasts ( Kong et al., 1999 ; Suda et al., 1999 ; Arron and Choi, 2000 ; Hofbauer et al., 2000 ; Takahashi et al., 2002 ; Boyle et al., 2003 ).”
Self-citationThe role of gut microbiota in bone homeostasis
Behera, J., Ison, J., Tyagi, S. C., & Tyagi, N. (2020) · Bone · doi:10.1016/j.bone.2020.115317 · Cited by 162
Control of RANKL gene expression
O'Brien, C. A. (2010) · Bone · doi:10.1016/j.bone.2009.08.050 · Cited by 162
RANK–RANKL signalling in cancer
Renema, N., Navet, B., Heymann, M.-F., Lezot, F., & Heymann, D. (2016) · Bioscience Reports · doi:10.1042/bsr20160150 · Cited by 161
Osteoimmunology: Interactions of the Immune and Skeletal Systems
Rho, J., Takami, M., & Choi, Y. (2004) · Molecules and Cells · doi:10.1016/s1016-8478(23)12997-9 · Cited by 162
Osteoimmunology: Inflammatory osteolysis and regeneration of the alveolar bone
Gruber, R. (2019) · Journal of Clinical Periodontology · doi:10.1111/jcpe.13056 · Cited by 159
Osteoprotegerin ligand: a regulator of immune responses and bone physiology
Kong, Y.-Y., Boyle, W. J., & Penninger, J. M. (2000) · Immunology Today · doi:10.1016/s0167-5699(00)01718-7 · Cited by 162
Self-citationXu, J., Tan, J. W., Huang, L., Gao, X.-H., Laird, R., Liu, D., Wysocki, S., & Zheng, M. H. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.11.2178 · Cited by 160
Activated CD4+CD25+ regulatory T cells inhibit osteoclastogenesis and collagen-induced arthritis
Kelchtermans, H., Geboes, L., Mitera, T., Huskens, D., Leclercq, G., & Matthys, P. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.086066 · Cited by 160
Grant, E. P., Picarella, D., Burwell, T., Delaney, T., Croci, A., Avitahl, N., Humbles, A. A., Gutierrez-Ramos, J.-C., Briskin, M., Gerard, C., et al. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020205 · Cited by 158
Do RANKL inhibitors (denosumab) affect inflammation and immunity?
Ferrari, S., & Ferrari, S. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1326-y · Cited by 170
Interactions between immune and bone cells: new insights with many remaining questions
Lorenzo, J. (2000) · Journal of Clinical Investigation · doi:10.1172/jci11089 · Cited by 156
The Critical Role of IL-34 in Osteoclastogenesis
Chen, Z., Buki, K., Vääräniemi, J., Gu, G., & Väänänen, H. K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018689 · Cited by 154
Zheng, Z., Li, X. Y., Ding, J., Jia, J., & Zhu, P. (2007) · Rheumatology · doi:10.1093/rheumatology/kem284 · Cited by 165
Bettis, T., Kim, B.-J., & Hamrick, M. W. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4570-1 · Cited by 153
Tumor necrosis factor-α antagonists for the treatment of rheumatic diseases
Criscione‐Schreiber, L. G., & Clair, E. W. S. (2002) · Current Opinion in Rheumatology · doi:10.1097/00002281-200205000-00002 · Cited by 151
Kim, K., Cho, M., Lee, S., Oh, H.-J., Kang, C.-M., Ju, J. H., Min, S., Cho, Y. G., Park, S., & Kim, H. (2007) · Immunology Letters · doi:10.1016/j.imlet.2007.03.004 · Cited by 158
The role of immune responses in bone loss during periodontal disease
Baker, P. J. (2000) · Microbes and Infection · doi:10.1016/s1286-4579(00)01272-7 · Cited by 151
Pettit, A. R., Walsh, N. C., Manning, C., Goldring, S. R., & Gravallese, E. M. (2006) · Rheumatology · doi:10.1093/rheumatology/kel045 · Cited by 151
“Recent studies investigating the pathogenic mechanisms of bone destruction in animal models of arthritis have provided substantial evidence that the osteoclast is the cell type primarily responsible for focal bone erosion, and that generation and activity of osteoclasts is dependent upon receptor activator of NF- B li…”
BackgroundInfluentialResorbability of bone substitute biomaterials by human osteoclasts
Schilling, A. F., Linhart, W., Filke, S., Gebauer, M., Schinke, T., Rueger, J. M., & Amling, M. (2003) · Biomaterials · doi:10.1016/j.biomaterials.2003.10.079 · Cited by 174
“However, since the discovery of RANKL, a molecule required for osteoclast differentiation [8–10], it has become possible to generate osteoclasts from mononuclear precursors in vitro, without the support of osteoblastic stromal cells.”
BackgroundRegulatory T cells in the bone marrow microenvironment in patients with prostate cancer
Zhao, E., Wang, L., Dai, J., Kryczek, I., Wei, S., Vatan, L., Altuwaijri, S., Sparwasser, T. D., Wang, G., Keller, E. T., et al. (2012) · OncoImmunology · doi:10.4161/onci.1.2.18480 · Cited by 170
“Activated T cells produce RANKL and can directly trigger osteoclastogenesis in vitro through RANK, while systemic activation of T cells in vivo results in a RANKL-mediated increase in osteoclastogenesis and bone loss.(40) Although RANKL/RANK pathway is involved in Treg cell expansion in the cancer metastasis to bone m…”
BackgroundOsteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice.
Schett, G., Redlich, K., Hayer, S., Zwerina, J., Bolon, B., Dunstan, C., Görtz, B., Schulz, A., Bergmeister, H., Kollias, G., et al. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11150 · Cited by 150
Self-citationXu, H., & Remmen, H. V. (2021) · Skeletal Muscle · doi:10.1186/s13395-021-00280-7 · Cited by 189
“Receptor-activator of nuclear factor-κB (RANK), its ligand RANKL, and the soluble decoy receptor osteoprotegerin (OPG) are members of the tumor necrosis factor superfamily that regulate bone remodeling [29, 32].”
Lerner, U. H. (2004) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/154411130401500202 · Cited by 177
How we got attached to Actinobacillus actinomycetemcomitans: a model for infectious diseases
Fine, D. H., Kaplan, J. B., Kachlany, S. C., & Schreiner, H. C. (2006) · Periodontology 2000 · doi:10.1111/j.1600-0757.2006.00189.x · Cited by 184
Olsen, I., Taubman, M. A., & Singhrao, S. K. (2016) · Journal of Oral Microbiology · doi:10.3402/jom.v8.33029 · Cited by 147
Soluble RANKL and risk of nontraumatic fracture.
Schett, G. (2004) · JAMA · doi:10.1001/jama.291.9.1108 · Cited by 146
Mizuno, A., Kanno, T., HOSHI, M., Shibata, O., Yano, K., Fujise, N., Kinosaki, M., Yamaguchi, K., Tsuda, E., Murakami, A., et al. (2002) · Journal of Bone and Mineral Metabolism · doi:10.1007/s007740200049 · Cited by 156
Childs, L. M., Paschalis, E. P., Xing, L., Dougall, W. C., Anderson, D., Boskey, A. L., Puzas, J. E., Rosier, R. N., O'Keefe, R. J., Boyce, B. F., et al. (2002) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2002.17.2.192 · Cited by 146
T he R ole of A cquired I mmunity and P eriodontal D isease P rogression
Teng, Y.-T. A. (2003) · Critical Reviews in Oral Biology & Medicine · doi:10.1177/154411130301400402 · Cited by 146
“RANK-L and its receptor RANK signaling pathway are essential for T-cell/dendritic-cell interactions, dendritic cell survival, lymph node formation, and organogenesis (Anderson et al., 1997; Kong et al., 1999a).”
InfluentialColucci, S., Brunetti, G., Rizzi, R., Zonno, A., Mori, G., Colaianni, G., Del Prete, D., Faccio, R., Liso, A., Capalbo, S., et al. (2004) · Blood · doi:10.1182/blood-2004-02-0474 · Cited by 146
Metadata
- Authors
- Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., Wong, T., Campagnuolo, G., Moran, E., Bogoch, E. R., Van, G., Nguyen, L. T., Ohashi, P. S., Lacey, D. L., Fish, E., Boyle, W. J., & Penninger, J. M.
- Affiliations
- Amgen (Canada) (CA)
- Amgen (United States) (US)
- St. Michael's Hospital (CA)
- University of Toronto (CA)
- ORCID
- Venue
- Nature
- Published
- 1999-11
- Volume
- 402
- Issue
- 6759
- Pages
- 304-309
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1677043489
- Cited by
- 1,856
- References
- 24
- Citations by year
- 2026: 17 · 2025: 33 · 2024: 36 · 2023: 33 · 2022: 25 · 2021: 36 · 2020: 47 · 2019: 43 · 2018: 38 · 2017: 59 · 2016: 64 · 2015: 82 · 2014: 80 · 2013: 85 · 2012: 77
- FWCI
- 26.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Cystic Fibrosis Foundation
- U.S. Public Health Service
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Rheumatology › Osteomyelitis and Bone Disorders Research
- Keywords
- osteoprotegerin ligand, osteoprotegerin, RANK, activated T cells, adjuvant-induced arthritis, bone loss, osteoclastogenesis, joint destruction, cartilage destruction, T cell activation, bone remodeling, osteoclasts
- MeSH terms
- Animals, Arthritis, Experimental, Bone and Bones, Bone Resorption, Carrier Proteins, Cartilage, Cells, Cultured, Glycoproteins, Humans, Lymphocyte Activation, Membrane Glycoproteins, Mice, Inbred C57BL, Rats, Inbred Lew, T-Lymphocytes, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Coculture Techniques, Mice, Rats, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.